Adherence to deferasirox among beta-thalassemia major children - A cross-sectional study in a tertiary care hospital by Panda, K et al.
Vol 5 | Issue 1 | Jan 2018 Indian J Child Health 38
Original Article
Adherence to deferasirox among beta-thalassemia major children - A 
cross-sectional study in a tertiary care hospital
K Panda, N R Mishra, S K Jena
From 1Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Sambalpur, Odisha, Bhubaneswar, India
Correspondence to: N R Mishra Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, 
Sambalpur, Odisha, India. Phone: +91-9337797072. E-mail: drnihar.mishra@gmail.com
Received - 23 November 2017 Initial Review - 06 December 2017 Published Online - 19 January 2018
Repeated blood transfusion is the mainstay of care for children with beta-thalassemia major [1]. There are two major benefits of transfusion as follows: First, it corrects 
anemia, and second, it suppresses the ineffective erythropoiesis. 
Chronic blood transfusions (CBT) prevent many of the serious 
growth, skeletal, and neurological complications of beta-
thalassemia major. However, once began, the transfusion-related 
complications become a major source of morbidity out of which 
body iron overloading is an important issue which necessitates 
the use of iron chelators [2]. Iron chelation therapy significantly 
improves myocardial T2 and left ventricular function [3-5]. Since 
long, the standard iron chelation therapy in thalassemia used to 
be deferoxamine [6], a subcutaneous or intravenous infusion, 
generally 8–12 h per day, 5–7 days per week, and was associated 
with poor adherence in some patients [7]. We all know that 
good adherence is essential to reduce the risk of complications 
and mortality due to iron overload. In 2005, deferasirox, an oral 
chelator, was approved for use by the United States Food and Drug 
Administration. Deferasirox has been proved to be very safe and 
effective in beta-thalassemia major children; however, the issue 
arises about the adherence to this novel oral iron chelator [8].
Adherence to long-term therapy for chronic diseases in 
developed countries averages around 50% [9]. In developing 
countries, the adherence rates are even poor. Poor adherence to 
medication is widely observed in chronic diseases and is a major 
challenge in clinical practice. Poor adherence to medication poses 
a negative impact on treatment outcomes and acts as a burden 
to heath-care cost [10]. In India, very few studies have studied 
the factors that impact adherence to deferasirox chelation therapy. 
Therefore, this study was conducted to observe the adherence to 
oral deferasirox among transfusion dependent beta-thalassaemic 
children.
MATERIALS AND METHODS
After getting due approval from the institutional ethics committee, 
this observational, analytical, and cross-sectional study was 
conducted at the thalassemia day care center of a 750-bedded 
tertiary care teaching institution of western Odisha, India. This 
study spanned over a period of 1 year from November of 2015 
to October of 2016. The study population and target population 
being the same, i.e., all beta-thalassemia major children receiving 
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CBT and receiving oral deferasirox. The major confounders of 
this study are age (in years), gender, literacy of informants, and 
type of family. The major outcome analyzed was the percentage 
of thalassaemic children with good adherence to deferasirox. 
The inclusion criteria being the diagnosed cases of beta-
thalassemia major children (based on high-performance liquid 
chromatography report) aged between 2 and 14 years of age in 
whom iron chelation was started after getting transfused with at 
least 20 units of packed red blood cell and with a serum ferritin 
level of >1000 μg/dL. Thalassemia heterozygotes, sickle-thal 
children, thalassemia with HbD or HbE and critically ill children 
were excluded from the study.
After satisfying the predefined inclusion and exclusion 
criteria, 91 children were enrolled for the study using simple 
consecutive sampling. The children were excluded who were 
coming for the second time to the hospital. After explaining in 
detail about the study procedures in the local language, written 
informed consent was obtained from the legal heir of the study 
participants. The basic demographic profiles were collected by 
interview schedule of informants. All primary caregivers were 
handed over a pretested and prevalidated questionnaire called 
Morisky Medication Adherence Scale (MMAS-8) [11] which is 
a self-reporting questionnaire available in English. The MMAS-8 
was translated into local vernacular language and was tested 
among primary caregivers of 10 thalassaemic children, and 
necessary corrections were done to the translated version of the 
questionnaire with expert consultation which was again applied 
to another 10 thalassemics. This translated questionnaire was 
assessed for reliability with a Cronbach’s alpha 0.72.
MMAS-8 (Fig. 1) is composed of 8 items, out of which the 
items from 1 to 7 are yes/no questions (except item 5) where no 
answers receive a score of 1.0, and yes answers receive a score 
of 0. The score is reversed for item 5. Item 8 is measured based 
on a 1 to 5 Likert scale. The total scores range between 0 and 
8, where 8 is considered as high adherence, 6–8 as moderate 
adherence, and <6 as poor adherences. The confidentiality of data 
is well maintained. Double data entry was done by two separate 
persons (principal investigator and co-principal investigator). 
Data checking was done manually by them. Data validation was 
done using EpiData version 3.0. Basic demographic characters 
such as age, gender, level of literacy of primary caregiver, and 
type of family were collected.
The outcome variables were percentage of patients with 
high, moderate, and poor adherence, respectively and inter-
group correlation with age, gender, serum ferritin levels, and 
level of literacy (aged 7 years or above who can read and write 
with understanding) of the primary caregiver and type of family 
(nuclear family defined as family group consisting of two parents 
and their children (one or more) and/or joint family defined as a 
family in which many generations living in the same household, 
all bound by the common relationship), respectively, was studied. 
The causes of nonadherence were also collected in the three 
different groups.
Data normalcy was tested using Shapiro-Wilk test where 
p>0.05 indicated normal data distribution. Descriptive statistics 
included means and standard deviations for continuous variables 
and percentages for categorical variables. Adherence levels 
across groups were compared using Chi-square and/or Fischer’s 
exact test. Multivariate analysis was performed between the 
three groups. The results were considered to be significant where 
p<0.05.
RESULTS
Among 91 total patients, 67% (61) were male and 33% (30) were 
female. The mean age (in years) was 9.8±2.6 (range 6–14 years). 
Poor adherence to deferasirox was found in 42.9% (39) of the 
study participants, 48.4% (45) were moderately adherent and 
7.5% (7) of the patients reported to be highly adherent. To study 
the association between age and adherence, we did one-way 
ANOVA test (Table 1) and found that there is the high statistically 
significant difference in the mean age of the patients belonging to 
the three different groups (highly adherent, moderately adherent, 
and poorly adherent) as evidenced by F=22.2 (2,88), p=0.000. After 
doing Tukey’s post-hoc analysis, it was observed that the mean age 
of highly adherent group (7.6±1.7 years) was significantly lower 
than that of poorly adherent group (11.5±1.9 years), p=0.000 and 
the mean age in moderately adherent group (8.7±2.3 years) too 




1. Do you sometimes forget to take your 
medication?
2. People sometimes miss taking their 
medications for reasons other than forgetting, 
over the past 2 weeks, were there any days when 
you did not take your medication?
3. Have you ever cut back or stopped taking 
your medication without telling your doctor 
because you felt worse when you took it?
4. When you travel or leave home, do you 
sometimes forget to bring your medication?
5. Did von take all your medication yesterday?
6. When you feel like your symptoms are under 
control, do you sometimes stop taking your 
medication?
7. Taking medication every day is a real 
inconvenience for some people. Do you ever 
feel hassled about sticking to your treatment 
plan?
8. How often do you have difficulty 
remembering to take all your medication?
Never/rarely
Once in a while
Sometimes
All the time
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We also found the statistically significant difference in 
the mean serum ferritin levels of the three respective groups 
{F=38.25 (2,88), p=0.000}. The mean serum ferritin level (in 
ng/ml) of the highly adherent group (1281.71±326.85) was 
significantly lower than that of moderately adherent group 
(2065.87±923.77), (p=0.001) and that of the poorly adherent group 
(3677.00±1046.90), p=0.000. Among males and females, there 
was no significant difference in the level of adherence (Pearson 
Chi-square=2.016 (2), p=0.365). Within all males, the mean age of 
the three different groups, respectively, are significantly different 
from each other as evidenced by F=13.85 (2,58), p=0.000. The 
mean age (in years) in poorly adherent males (11.3±1.9) was 
significantly higher than that of moderately adherent males 
(8.7±2.4), p=0.000 and that of highly adherent males (6.8±1.3), 
p=0.000 too. However, among females, only the poorly adherent 
ones differed from the moderately adherent ones in their respective 
mean age (11.8±1.9 vs. 8.8±2.1), p=0.002.
Similarly, the mean serum ferritin levels (in ng/ml) among 
highly adherent males (1318.40±388.04) was significantly lower 
than that of moderately adherent males (2172.39±952.61), p=0.000 
and that of poorly adherent males (3541.48±1033.69), p=0.000. 
Among females, the mean serum ferritin levels (in ng ml) among 
highly adherent females (1190.00±123.03) was not significantly 
lower than that of moderately adherent females (1772.92±803.66), 
p=0.087. The overall literacy of the primary caregivers was 49.5%. 
The association between literacy and level of adherence was highly 
statistically significant (Pearson Chi-square=15.533 (2), p=0.000). 
Thirty-six percent of the children belonged to nuclear families and 
belonging to a nuclear family was strongly associated with high 
adherence (Pearson Chi-square=9.355 (2), p=0.009).
DISCUSSION
In the 91 patients enrolled, a male preponderance (67%) was 
observed. A similar preponderance of males (69.5%) was 
observed in studies conducted previously at Odisha, India [12]. 
The overall high adherence to deferasirox was very low in this 
study (7.5%) with younger children being more adherent than 
older ones. This may be attributed to the fact that more care is 
being taken by their parents when the children are younger or 
maybe older children are asked to take their medication on their 
own which might have led to poor reported adherence in them. A 
similar finding was observed in a study done in Jordan in 2014, 
in which poor adherence to deferasirox among older children was 
attributed to lack of parenteral monitoring [13].
As expected the serum ferritin values are lower in more adherent 
children which suggests that adherence to deferasirox effectively 
reduced iron overload. A previous study also showed a significant 
decrease in serum ferritin levels with deferasirox treatment in 
296 transfusion-dependent β thalassemia patients [14]. Not 
much effect of gender predisposition on the level of adherence 
could be observed here. It implies primary caregivers may not be 
discriminating their children on the basis of gender.
The literate primary caregiver was associated with good 
adherence. This may be because parents with better literacy 
levels can understand the need of oral iron chelator for their 
children which encourages them to ensure better compliance. 
A child belonging to a nuclear family was associated with better 
adherence in this study which may be attributed to more attention 
to children in a small nuclear family.
This study provides an opportunity to target interventions 
directed to improve adherence levels among beta-thalassemia 
major children receiving CBT. As our state is a resource poor 
setting and the part of the state where we are residing is the 
poorest among the poor in terms of literacy and family structure, 
and the adherence to the drug was pitiable. Hence, in our opinion, 
a multidisciplinary approach in all aspects is needed in future to 
increase the adherence of the oral iron chelator - deferasirox in 
beta-thalassaemic children.
Being a facility-based study, the results of this study cannot 
be generalized to the whole population, and there are chances of 
recall bias due to self-reporting by patient caregivers. A qualitative 
analysis would be a better option in this scenario, but could not 
be done due to lack of resources. Hence, a follow-up qualitative 
study at a definite regular time interval by the investigator should 
be done in the future.
CONCLUSION
Poor adherence was seen in less than one-half of the study 
participants. Illiteracy, higher age, and joint family are the 
surrogate parameters of poor adherence to the medication.
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